ロード中...
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
BACKGROUND: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated...
保存先:
| 出版年: | BMC Neurol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4397697/ https://ncbi.nlm.nih.gov/pubmed/25880756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0305-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|